Table 1.
Overview of samples and processed brain tissue for Fig. 2
Case # | Age at death [years] | Gender | Disease duration [years] | PMI [hours] | McKeith | Braak LB | Braak NFT | CERAD | FC | CC | EC | Str. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Control 1 | 77 | Male | 83 | 2 | Absent | x | ||||||
Control 2 | 74 | Female | 53 | 3 | Absent | x | ||||||
Control 3 | 95 | Female | 39 | 4 | Moderate | x | x | |||||
Control 4 | 99 | Female | 32 | 4 | Frequent | x | x | |||||
Control 5 | 87 | Male | 39 | 1 | Absent | x | x | |||||
Control 6 | 57 | Female | 13 | x | ||||||||
Control 7 | 86 | Male | 10 | x | ||||||||
Control 8 | 92 | Male | 24 | 2 | Absent | x | x | |||||
Control 9 | 92 | Male | 23 | 2 | Sparse | x | x | |||||
Control 10 | 54 | Male | 6 | 0 | Absent | x | x | |||||
Control 11 | 60 | Male | x | |||||||||
Control 12 | 75 | Female | 4 | x | ||||||||
Control 13 | 81 | Female | 2 | x | ||||||||
Control 14 | 75 | Female | 3 | x | ||||||||
Control 15 | 81 | Male | 3 | x | ||||||||
Control 16 | 78 | Male | 2 | x | ||||||||
Control 17 | 79 | Female | 2 | x | ||||||||
Control 18 | 70 | Male | 2 | x | ||||||||
Control 19 | 63 | Male | 3 | x | ||||||||
Control 20 | 87 | Female | 3 | x | ||||||||
Control 21 | 88 | Female | 5 | x | ||||||||
Control 22 | 90 | Male | 46 | 4 | Moderate | x | ||||||
Control 23 | 76 | Male | 79 | 2 | Absent | x | x | |||||
Control 24 | 84 | Female | 54 | 2 | Absent | x | x | |||||
Control 25 | 83 | Female | 99 | 2 | Sparse | x | x | |||||
Control 26 | 89 | Male | 156 | 3 | Sparse | x | x | |||||
Control 27 | 82 | Female | 91 | 2 | Sparse | x | x | |||||
Control 28 | 84 | Male | 79 | 1 | x | |||||||
DLB 1 | 77 | Male | 2.5 | 29 | Neocortical | 6 | 2 | Moderate | x | |||
DLB 2 | 71 | Male | 5 | 22 | Neocortical | 6 | 3 | Moderate | x | x | x | |
DLB 3 | 72 | Male | 8 | 89 | Neocortical | 6 | 3 | Absent | x | x | x | |
DLB 4 | 84 | Male | 10 | 72 | Neocortical | 6 | 2 | Absent | x | x | x | |
DLB 5 | 73 | Female | 6 | 73 | Neocortical | 6 | 3 | Absent | x | x | x | |
DLB 6 | 76 | Male | 8 | 13 | Neocortical | 6 | 2 | Sparse | x | |||
DLB 7 | 81 | Male | 5 | 26 | Neocortical | 6 | 3 | Moderate | x | x | x | |
DLB 8 | 81 | Male | 3 | 81 | Neocortical | 6 | 3 | Moderate | x | x | x | |
DLB 9 | 60 | Male | 8 | 24 | Neocortical | 6 | 1 | Moderate | x | x | ||
DLB 10 | 67 | Male | 7 | 40 | Neocortical | 6 | 3 | Moderate | x | x | ||
DLB 11 | 79 | Female | 12 | Neocortical | 6 | 4 | Sparse | x | ||||
DLB 12 | 83 | Male | 8 | 54 | x | x | ||||||
DLB 13 | 63 | Female | 10 | 4 | x | x | ||||||
DLB 14 | 81 | Female | Neocortical | 6 | 3 | x | ||||||
DLB 15 | 67 | Female | Neocortical | 6 | 4 | x | ||||||
PD 1 | 42 | Male | 4 | 42 | Neocortical | 6 | 4 | x | x | |||
PD 2 | 78 | Male | 3 | 24 | Neocortical | 6 | 0 | Absent | x | x | ||
PD 3 | 83 | Female | 8 | 99 | Neocortical | 6 | 3 | x | x | |||
PD 4 | 76 | Male | 6 | 85 | Neocortical | 6 | 6 | x | x | |||
PD 5 | 76 | Male | 7 | 49 | Neocortical | 6 | 1 | Sparse | x | x | ||
PD 6 | 82 | Male | 11 | 7 | Neocortical | 6 | 2 | Absent | x | x | x | |
PD 7 | 81 | Male | 13 | 46 | Neocortical | 6 | 2 | Absent | x | x | ||
PD 8 | 74 | Male | 16 | 55 | Neocortical | 6 | 2 | Absent | x | |||
PD 9 | 79 | Female | 15 | 65 | Neocortical | 6 | 2 | Mild | x | x | ||
PD 10 | 79 | Female | 14 | 27 | Neocortical | 6 | 4 | Absent | x | x | ||
PD 11 | 75 | Male | 22 | 11 | Neocortical | 6 | 2 | Absent | x | x | ||
PD 12 | 76 | Male | 10 | 29 | Neocortical | 6 | 2 | Absent | x | |||
PD 13 | 87 | Male | 38 | Limbic | 3 | 1 | Sparse | x | ||||
PD 14 | 73 | Male | 24 | Limbic | 4 | x | ||||||
PD 15 | 87 | Female | 6 | Limbic | 4 | 2 | Sparse | x |
DLB dementia with Lewy bodies, PD Parkinson’s disease, PMI post-mortem interval, LB Lewy bodies, NFT neurofibrillary tangles, CERAD Consortium to Establish a Registry for Alzheimer’s Disease, FC frontal cortex, CC cingulate cortex, EC entorhinal cortex, Str. striatum